Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLG | P54098 | 3/20 | 0.53 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | P2RY2 | P41231 | 7/20 | 0.43 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.43 |
| ▸ | P2RY6 | Q15077 | 3/20 | 0.43 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.37 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20879410 | 0.84 | POLG (0.59) | POLGFGFR1POLBP2RY2P2RY4 | |
| SCHEMBL18840676 | 0.84 | POLG (0.59) | POLGFGFR1POLBP2RY2P2RY4 | |
| SCHEMBL22475057 | 0.81 | POLG (0.54) | POLGFGFR1POLBP2RY2P2RY4 | |
| SCHEMBL20879524 | 0.79 | POLG (0.55) | POLGFGFR1POLBP2RY2P2RY4 | |
| SCHEMBL21756756 | 0.76 | POLG (0.50) | POLGFGFR1POLBP2RY2P2RY4 | |
| SCHEMBL25651894 | 0.76 | POLG (0.56) | POLGPOLBP2RY2P2RY4P2RY6 | |
| SCHEMBL6715771 | 0.75 | POLG (0.62) | POLGPOLBP2RY2P2RY4P2RY6 | |
| SCHEMBL6715777 | 0.75 | POLG (0.62) | POLGPOLBP2RY2P2RY4P2RY6 | |
| SCHEMBL16807802 | 0.75 | POLG (0.62) | POLGPOLBP2RY2P2RY4P2RY6 | |
| SCHEMBL22678641 | 0.75 | POLG (0.62) | POLGPOLBP2RY2P2RY4P2RY6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220162251-A1 | NUCLEOTIDE ANALOGUES | QIAGEN SCIENCES, LLC | 2022-05-26 | — | — | US | disclosed |
| US-11046726-B2 | Nucleotide analogues | QIAGEN SCIENCES, LLC (US) | 2021-06-29 | — | — | US | disclosed |
| US-20180208774-A1 | NUCLEOTIDE ANALOGUES | IsoPlexis Corporation | 2018-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11046726-B2 | Nucleotide analogues | NT5C3B, SAMHD1, DUT | POLG 176/4885FGFR1 4808/4885POLB 28/4885 |
| US-20220162251-A1 | NUCLEOTIDE ANALOGUES | NT5C3B, SAMHD1, DUT | POLG 176/4885FGFR1 4808/4885POLB 28/4885 |
| US-20180208774-A1 | NUCLEOTIDE ANALOGUES | NT5C3B, SAMHD1, DUT | POLG 176/4885FGFR1 4808/4885POLB 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.